Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists

In a large emulated-trial analysis of people with type 2 diabetes and stage 4-5 CKD, starting an SGLT2 inhibitor rather than a GLP-1 receptor agonist was linked to fewer kidney complications and a lower chance of needing dialysis, with similar heart and survival outcomes.